Combined effect of Tislelizumab and chemotherapy on tumor control rate and prognosis in patients with small cell lung cancer
Adopting the conventional combination of Tislelizumab and chemotherapy to treat SCLC can downregulate tumor marker levels, improve immune function, enhance treatment efficacy, and ensure disease prognosis. Longer follow-up is needed to confirm long-term prognostic benefits.
Authors
- Na Zhong (ORCID: https://orcid.org/0000-0001-5161-6831)
- Wei Zhuang (ORCID: https://orcid.org/0009-0008-9907-1576)
- Meiying Zhong (ORCID: https://orcid.org/0009-0002-4581-8394)
Institutions
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Jiangxi Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Pakistan Journal of Medical Sciences
- Published
- 2025-05-02
- DOI
- https://doi.org/10.12669/pjms.41.5.11530
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00